Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
96.23 USD | +0.03% | +1.91% | +1.23% |
Apr. 24 | Earnings Flash (AMED) AMEDISYS Reports Q1 EPS $1.03 | MT |
Apr. 24 | Amedisys, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- With a 2024 P/E ratio at 25.24 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.23% | 3.14B | B- | ||
0.00% | 1.94B | - | ||
+68.75% | 706M | D+ | ||
-14.59% | 443M | - | ||
-45.44% | 310M | - | ||
-14.18% | 191M | - | ||
-16.65% | 129M | - | ||
+3.85% | 69.12M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMED Stock
- Ratings Amedisys, Inc.